R
Robert Charles Ladner
Researcher at Takeda Pharmaceutical Company
Publications - 99
Citations - 6698
Robert Charles Ladner is an academic researcher from Takeda Pharmaceutical Company. The author has contributed to research in topics: Phage display & Kunitz domain. The author has an hindex of 32, co-authored 99 publications receiving 6534 citations. Previous affiliations of Robert Charles Ladner include University of Nottingham.
Papers
More filters
Patent
Directed evolution of novel binding proteins
Robert Charles Ladner,Sonia Kosow Guterman,Bruce L. Roberts,William Markland,Arthur C. Ley,Rachel Baribault Kent +5 more
TL;DR: In this article, a structural signal called for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) is introduced into a genetic package.
Journal ArticleDOI
Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity
Rene Hoet,Edward H. Cohen,Rachel Baribault Kent,Kristin L. Rookey,Sonia Schoonbroodt,Shannon Hogan,Louise Rem,Nicolas Frans,Marc Daukandt,Henk Pieters,Rob van Hegelsom,Nicole Coolen-van Neer,Nastri Horacio G,Isaac J. Rondon,Jennifer A. Leeds,Simon E. Hufton,Lili Huang,Irina Kashin,Mary Devlin,Guannan Kuang,Mieke Steukers,Malini Viswanathan,Andrew E. Nixon,Daniel J. Sexton,Hennie R. Hoogenboom,Robert Charles Ladner +25 more
TL;DR: The construction of human Fab libraries having a unique combination of immunoglobulin sequences captured from human donors and synthetic diversity in key antigen contact sites in heavy-chain complementarity-determining regions 1 and 2 are reported.
Patent
Generation and selection of novel DNA-binding proteins and polypeptides
TL;DR: In this article, a selection vector is used to reduce artifacts and a variety of methods, e.g., variegation to obtain proteins binding symmetrized forms of the half-targets and heterodimerization to obtain a protein binding the entire asymmetric target.
Journal ArticleDOI
Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis.
Laetitia Devy,Lili Huang,Laurent Naa,Niranjan Yanamandra,Henk Pieters,Nicolas Frans,Edward F. Chang,Qingfeng Tao,Marc Vanhove,Annabelle Lejeune,Reinoud van Gool,Daniel J. Sexton,Guannan Kuang,Douglas Rank,Shannon Hogan,Csaba Pazmany,Yu Lu Ma,Sonia Schoonbroodt,Andrew E. Nixon,Robert Charles Ladner,Rene Hoet,Paula Henderikx,Chris TenHoor,Shafaat A. Rabbani,Maria-Luisa Valentino,Clive R. Wood,Daniel T. Dransfield +26 more
TL;DR: In this paper, the authors used a highly selective fully human MMP-14 inhibitory antibody discovered using phage display technology, which blocked proMMP-2 processing on tumor and endothelial cells, inhibited angiogenesis, and slowed tumor progression and formation of metastatic lesions.
Journal ArticleDOI
Phage display-derived peptides as therapeutic alternatives to antibodies.
TL;DR: Results from phage display in finding peptide drug candidates are reviewed, some business benefits of developing peptides are concluded, and novel strategies have been developed for inhibiting receptor-ligand interactions are reviewed.